NYSE:ABT 26 November 2025 - 27 January 2026

Shares of Abbott Laboratories dropped roughly 1.2% to $107.49 by midday Tuesday, erasing some of Monday’s gains. A Form 4 filing dated Jan. 26 revealed that Chairman and CEO Robert Ford purchased 18,800 shares on Jan. 23.

Shares of Abbott Laboratories climbed about 1% on Monday after a regulatory filing revealed Chairman and CEO Robert Ford purchased nearly $2 million in company stock. The shares traded up 1% at $108.49 midday, having reached $110.20 earlier. Ford acquired 18,800 shares through the Ford Family Trust at a weighted average price of $107.13, with individual prices between $106.735 and $107.485. He now holds 253,305 shares directly and another 216,203 indirectly via the trust.

Abbott Laboratories shares head into Monday weighed down, following last week’s selloff and another wave of broker price-target downgrades.

Abbott Laboratories shares ended Friday at $107.42, slipping 1.1% after tumbling nearly 10% the previous day. Investors are reacting to a quarterly sales shortfall and a weaker 2026 forecast. When trading resumes Monday, the nutrition segment remains the primary concern for many analysts.

Dec. 25, 2025 — Abbott Laboratories heads into the year-end stretch with a rare mix of near-term product momentum and headline-level risk management. Over the past several weeks—culminating in key December announcements—Abbott has secured U.S. FDA approval for a next-generation atrial fibrillation ablation platform, expanded its push into consumer biowearables, navigated an FDA early alert tied to certain FreeStyle Libre sensors, and doubled down on its diagnostics ambitions with a planned ~$23 billion enterprise-value acquisition of Exact Sciences.

Abbott Laboratories finished Christmas Eve trading modestly higher, then ticked up again in light after-hours action—an unsurprising pattern for a defensive healthcare name during a holiday-shortened session. Still, the setup into Friday’s reopening matters, because investors are balancing three big Abbott storylines: the new Volt™ PFA system clearance, a fresh dividend hike, and the pending Exact Sciences acquisition that could reshape Abbott’s diagnostics mix.